...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence
【24h】

Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence

机译:肝细胞癌患者以复发为主的血清肌酸激酶线粒体同工酶活性增加

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background & Aims: Mitochondrial isoenzyme of creatine kinase (MtCK) is reportedly highly expressed in hepatocellular carcinoma (HCC). Clinical relevance of serum MtCK activity in patients with HCC was assessed using a novel immuno-inhibition method. Methods: Among patients with cirrhosis caused by hepatitis B or C virus, 147 patients with HCC (12 with the first occurrence and 135 with recurrence) and 92 patients without HCC were enrolled. Results: Serum MtCK activity was higher in cirrhotic patients with HCC than in those without HCC or healthy subjects. Elevated serum MtCK activity in HCC patients decreased after radiofrequency ablation. In case of prediction of HCC, MtCK had a sensitivity of 62.6% and a specificity of 70.7% at a cut-off point of 8.0 U/L, with an area under the receiver operating curve of 0.722 vs. 0.713 for alpha-fetoprotein (AFP) and 0.764 for des-gamma-carboxy prothrombin (DCP). Among the HCC patients, serum MtCK activity was elevated in 52.9% individuals with serum AFP level <20 ng/ml and 63.2% individuals with serum DCP level <40 mAu/ml. Even in patients with a single HCC ≤2 cm, the sensitivity of serum MtCK activity for the prediction of HCC was 64.4%, which was comparable to the overall sensitivity. This increased activity was due to an increase in ubiquitous MtCK, not sarcomeric MtCK, and the enhanced mRNA expression of ubiquitous MtCK was observed in cell lines originating from HCCs in contrast to healthy liver tissues. Conclusions: Serum MtCK activity merits consideration as a novel marker for HCC to be further tested as for its diagnostic and prognostic power.
机译:背景与目的:据报道,肌酸激酶(MtCK)的线粒体同工酶在肝细胞癌(HCC)中高表达。使用新型的免疫抑制方法评估了肝癌患者血清MtCK活性的临床相关性。方法:在由乙型或丙型肝炎病毒引起的肝硬化患者中,纳入147例HCC患者(首次发生12例,复发135例)和92例未见HCC的患者。结果:肝硬化肝硬化患者的血清MtCK活性高于无肝硬化或健康受试者的肝硬化患者。射频消融后HCC患者血清MtCK活性升高。在预测为HCC时,MtCK在8.0 U / L的临界点的敏感性为62.6%,特异性为70.7%,接受者操作曲线下方的面积为甲胎蛋白0.722比0.713( AFP)和0.764(对于γ-羧基凝血酶原(DCP))。在HCC患者中,血清AFP水平<20 ng / ml的52.9%个体和血清DCP水平<40 mAu / ml的63.2%个体的血清MtCK活性升高。即使在单个HCC≤2 cm的患者中,血清MtCK活性预测HCC的敏感性仍为64.4%,与总体敏感性相当。这种增加的活性归因于普遍存在的MtCK的增加,而不是肌节MtCK的增加,并且与健康肝脏组织相比,在源自HCC的细胞系中观察到普遍存在的MtCK的mRNA表达增强。结论:血清MtCK活性值得考虑作为一种新的肝癌标志物,其诊断和预后能力尚待进一步检验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号